Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Impact on quality of life of alleviating carbohydrate counting for patients with type 1 diabetes using a novel insulin-plus-pramlintide artificial pancreas: a randomized controlled crossover trial

EF 2019-20

Résumé
"Type 1 diabetes is an autoimmune disease that results in the destruction of insulin-producing beta-islet cells in the pancreas, requiring people with Type 1 diabetes to received life-long exogenous supplementation of insulin, either in the form of multiple daily injections or continuous subcutaneous insulin infusion via a pump. The artificial pancreas is a newly developed therapy for people with diabetes involving a continuous glucose monitor that sends blood glucose information to an algorithm, which subsequently modulates the dose of of insulin a patient receives via their pump.A consequence of diabetes is the loss of amylin, a hormone co-secreted with insulin in the pancreas, responsible for increasing satiety, slowing down gastric emptying, and decreasing glucagon secretion (a hormone responsible for increased blood glucose). Pramlintide is an amylin analog which supplements insulin infusion as a treatment for diabetes.An indispensable requirement for insulin therapy is the need for carbohydrate counting when eating meals, to ensure that a commensurate insulin dose will be dispensed, and will adequately control post-meal blood glucose variations. This practice, however, can be burdensome and have a high risk of inaccuracy.I will conduct a qualitative assessment through questionnaires and interviews of the impact on participants' quality of life of an insulin-and-pramlintide artificial pancreas system that alleviates the need for carbohydrate counting. This project aims to demonstrate the system's efficacy in maintaining good glucose control, all-the-while addressing the concerns raised regarding carbohydrate counting. This will be the first qualitative study run by our lab, a necessary step in making this form of therapy available to patients on a wider scale."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428757
Name
COHEN ELISA
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Impact on quality of life of alleviating carbohydrate counting for patients with type 1 diabetes using a novel insulin-plus-pramlintide artificial pancreas: a randomized controlled crossover trial
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomedical; Carbohydrate-Coutning; Clinical Trial; Insulin; Pramlintide; Psychosocial; Qualitative; Quality-Of-Life; Semi-Structured Interviews; Type 1 Diabetes
Abstract
"Type 1 diabetes is an autoimmune disease that results in the destruction of insulin-producing beta-islet cells in the pancreas, requiring people with Type 1 diabetes to received life-long exogenous supplementation of insulin, either in the form of multiple daily injections or continuous subcutaneous insulin infusion via a pump. The artificial pancreas is a newly developed therapy for people with diabetes involving a continuous glucose monitor that sends blood glucose information to an algorithm, which subsequently modulates the dose of of insulin a patient receives via their pump.A consequence of diabetes is the loss of amylin, a hormone co-secreted with insulin in the pancreas, responsible for increasing satiety, slowing down gastric emptying, and decreasing glucagon secretion (a hormone responsible for increased blood glucose). Pramlintide is an amylin analog which supplements insulin infusion as a treatment for diabetes.An indispensable requirement for insulin therapy is the need for carbohydrate counting when eating meals, to ensure that a commensurate insulin dose will be dispensed, and will adequately control post-meal blood glucose variations. This practice, however, can be burdensome and have a high risk of inaccuracy.I will conduct a qualitative assessment through questionnaires and interviews of the impact on participants' quality of life of an insulin-and-pramlintide artificial pancreas system that alleviates the need for carbohydrate counting. This project aims to demonstrate the system's efficacy in maintaining good glucose control, all-the-while addressing the concerns raised regarding carbohydrate counting. This will be the first qualitative study run by our lab, a necessary step in making this form of therapy available to patients on a wider scale."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
COHEN, ELISA
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~